Form 4: Senseonics Director Douglas Prince to Receive Future Stock Compensation

Senseonics Holdings, Inc. Director Douglas S. Prince is set to acquire 17,069 shares of common stock on July 1, 2025, as part of his non-employee director compensation.

Summary

• Douglas S. Prince, a Director at Senseonics Holdings, Inc. (SENS), will acquire 17,069 shares of common stock.
• The transaction is scheduled to occur on July 1, 2025, at a price of $0.476 per share.
• These shares are being issued as compensation in lieu of quarterly retainer fees, pursuant to the Issuer's non-employee director compensation policy.
• The total value of this stock compensation is $8,124.84, calculated by dividing this amount by the closing price of $0.476 per share on the NYSE American on July 1, 2025.
• Following this transaction, Douglas S. Prince will beneficially own a total of 1,087,607 shares of Senseonics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's a routine compensation event, the director receiving shares aligns their interests with shareholders, which is generally viewed favorably. There are no negative implications.

Positives

• The acquisition of shares by a director increases insider ownership, potentially aligning management interests more closely with those of shareholders.
• The transaction is part of a pre-established non-employee director compensation policy, indicating a structured approach to executive incentives.

Future Outlook

The document details a future, pre-scheduled transaction related to director compensation, but does not provide broader forward-looking statements or guidance on company performance.

Management Comments

• Common stock was issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

Industry Context

Senseonics Holdings, Inc. operates in the medical device industry, specifically focusing on continuous glucose monitoring (CGM) systems. The practice of compensating non-employee directors with equity is a common governance and incentive mechanism across various industries, including medical technology, to align director interests with long-term shareholder value.

Comparison to Industry Standards

• Compensating non-employee directors with equity, such as common stock, is a standard practice across publicly traded companies, including those in the medical device sector.
• The specific value of the compensation ($8,124.84 quarterly) would typically be benchmarked against peer companies of similar size and complexity within the medical technology industry to ensure competitive and appropriate director remuneration.

Corporate Governance

Related Party Transactions

• The transaction involves the issuance of common stock to Douglas S. Prince, a director of Senseonics Holdings, Inc., as compensation for his services, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The issuance of shares to a director increases insider ownership, which can be seen as a positive signal of confidence in the company's future and better alignment of interests.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Key Dates

Keywords

Senseonics Holdings, SENS, Douglas S. Prince, Director Compensation, Insider Ownership, SEC Form 4, Stock Compensation, Medical Devices, Continuous Glucose Monitoring